STOCK TITAN

Exact Sciences (EXAS) 10-Q Filings

EXAS

Here are the 10-Q quarterly reports from Exact Sciences Corp (EXAS) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 10-Q covers the quarterly report filed between annual reports, so if you follow EXAS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EXAS filings page.

Rhea-AI Summary

Exact Sciences (EXAS) filed its quarterly report showing higher revenue and a narrower loss. Revenue for the quarter reached $850.739 million, up from $708.655 million a year ago, driven by both Screening and Precision Oncology. Net loss improved to $19.594 million from $38.236 million. Gross profit was $583.929 million.

By segment, Screening generated $666.240 million, while Precision Oncology contributed $184.499 million. For the first nine months, operating cash flow was $339.749 million, reflecting stronger collections and working capital. The company ended the quarter with $789.037 million in cash and cash equivalents and $214.058 million in marketable securities, totaling $1,003.095 million.

Convertible debt consisted of four series with a net carrying amount of $2.325 billion, and the company settled $249.172 million of 2025 notes in cash earlier in the year. Stockholders’ equity stood at $2.501 billion. Shares outstanding were 189,452,459 as of September 30, 2025; this is a baseline figure, not the amount being offered.